The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes

NCT03426085 on ClinicalTrials.gov · last registry update 2019-02-11

A small phase 2 — 44 participants, against a typical 110. Its estimated completion date, April 2020, has passed with no update to the record. Primary outcome, as filed: Sudomotor Function. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.

Status: UNKNOWN
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Eastern Virginia Medical School
Sponsor type: Other
Enrollment: 44
Started: 2016-05
Primary completion: 2020-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Sudomotor Function

Conditions studied

Autonomic Nervous System Diseases · Sweat Gland Diseases · Diabetic Neuropathy With Neurologic Complication

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.